A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

Feng Wang

Status: Not yet enrolling

Conditions: Colorectal Cancer Metastatic

Treatments: Drug: Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors

Study type: Observational

Funder types: Other

Identifiers

NCT06682247

CSIIT-Q88

Details and patient eligibility

About

This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced colorectal cancer patients.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Aged≥18 years
2. Histology-confirmed metastatic CRC (mCRC);
3. ECOG 0~2
4. At least one efficacy evaluation
5. Life expectancy of at least 3 months.

Exclusion criteria

1. Lack of follow-up data.
2. Chidamide stopped after less than two cycles.
3. Serious comorbidities that interfere with the efficacy or safety analysis

Trial design

200 participants in 1 patient group

chidamide + PD-1/PD-L1 inhibitors +Bevacizumab or tyrosine kinase inhibitors

Treatment:

Drug: Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors